Trade Mark Journal No.2025/036 5 September 2025

WO0000001870132 (44)

Office of origin: Israel

Date of International Registration:17 June 2025

Date of designation in the UK: 17 June 2025

International priority date claimed: 24 December 2024 (Israel) (379856)

Class 44: Medical analysis services; medical analysis services for the prediction of response to cancer treatment; medical analysis services for clinical outcomes associated with cancer treatment; medical analysis services for the prediction of side effects; medical analysis services for the prediction of side effects in a cancer patient; medical analysis services for identification of new drug targets for cancer treatment; medical analysis services for identification of new drug targets for the treatment of cancer drug side effects; medical analysis services for the prediction of response to cancer treatment based on computational analysis of patient's proteins; medical analysis services for predicting drug side effects based on computational analysis of patient's proteins; medical analysis services for discovering new targets for overcoming cancer drug resistance, based on computational analysis of patient's proteins; medical analysis services for discovering new targets for overcoming side effects associated with cancer treatment, based on computational analysis of patient's proteins; medical analysis services to support decision-making regarding the treatment of cancer patients; medical analysis services for the prediction of patients' response to cancer treatment and the identification of associated biological mechanisms; medical analysis services for the prediction of cancer treatment side effects and the identification of associated biological mechanisms.

ONCOHOST LTD

Representative: GEYRA KESTEN FRYDMAN, IP LAW, 100 Hahashmonaim Street, 6713317 Tel Aviv, ISRAEL